MedTrace Logo

A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

NCT07714668 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2026-07-20

No results posted yet for this study

Summary

This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.

Conditions

Interventions

DRUG

SYS6041, bevacizumab

SYS6041: RP2D dose, ivgtt, Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W

DRUG

SYS6041, carboplatin, bevacizumab

SYS6041: RP2D dose, ivgtt, Q3W Carboplatin: AUC5, ivgtt. Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W

DRUG

paclitaxel, carboplatin, bevacizumab

Paclitaxel:175mg/m2, ivgtt, Q3W Carboplatin: AUC5, ivgtt. Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W

DRUG

SYS6041, enlonstobart, bevacizumab

SYS6041: RP2D dose, ivgtt, Q3W Enlonstobart:360mg, ivgtt, Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W

Sponsors & Collaborators

  • CSPC Megalith Biopharmaceutical Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-04-30
Completion
2029-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07714668 on ClinicalTrials.gov